"In Sententiam" (colloquial translation "opinions or thoughts": Latin scholars may wince) is an occasional commentary on news and events in medicine and the life sciences. There are no deliberate themes, although there is a natural bias towards subjects that I've encountered through consulting assignments or even back in that misty time before self-employment. The sole purpose of the blog is to provide a diversion: for me, a short break from client-orientated writing and hopefully for those rare individuals pushed my way by the power of Google, a little ephemeral entertainment. The entire blog can be found at http://ayconsulting.blogspot.co.uk or you can go directly to posts of interest from the links below:
|
Updates "The immuno-oncology drug development pipeline: the next wave" is a commercial report detailing 60+ targets and the corresponding drug candidates and their development status and references over 150 companies. First published May 2018 (and continually updated). A sample report may be viewed and downloaded here Downloadable content. Occasional commentary and opinion can be found at http://ayconsulting.blogspot.co.uk Archived blog articles (before January 2013) are available from the downloadable content page "Business Development Basics. A Guide for Early-Stage Life Science Companies" can be found here:Downloadable content. Feedback, comments and suggestions for an expanded 2nd Edition are welcomed. 
©Alexander Yule 2017. All rights reserved |
|